Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Miller, KD; Rugo, HS; Cobleigh, MA; Marcom, PK; Chap, LI; Holmes, FA; Fehrenbacher, L; Overmoyer, BA; Reimann, JD; Vassel, AV; Langmuir, VK

Published Date

  • December 1, 2002

Published In

Volume / Issue

  • 76 /

Start / End Page

  • S37 - S37

Published By


  • 1

International Standard Serial Number (ISSN)

  • 0167-6806

Conference Name

  • 25th San Antonio Breast Cancer Symposium

Conference Location


Conference Start Date

  • December 11, 2002

Conference End Date

  • December 14, 2002